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ARTICLE
Tisagenlecleucel Model- Based Cellular Kinetic Analysis of 
Chimeric Antigen Receptor–T Cells
Andrew M. Stein1,*, Stephan A. Grupp2,3, John E. Levine4,5, Theodore W. Laetsch6,7, Michael A. Pulsipher8, Michael W. Boyer9, 
Keith J. August10 , Bruce L. Levine11,12, Lori Tomassian13, Sweta Shah13, Mimi Leung13, Pai-Hsi Huang13, Rakesh Awasthi14, 
Karen Thudium Mueller14, Patricia A. Wood13 and Carl H. June11,12
Tisagenlecleucel is a chimeric antigen receptor–T cell therapy that facilitates the killing of CD19+ B cells.  A model was de-
veloped for the kinetics of tisagenlecleucel and the impact of therapies for treating cytokine release syndrome (tocilizumab 
and corticosteroids) on expansion. Data from two phase II studies in pediatric and young adult relapsed/refractory B cell 
acute lymphoblastic leukemia were pooled to evaluate this model and evaluate extrinsic and intrinsic factors that may impact 
the extent of tisagenlecleucel expansion. The doubling time, initial decline half- life, and terminal half- life for tisagenlecleucel 
were 0.78, 4.3, and 220 days, respectively. No impact of tocilizumab or corticosteroids on the expansion rate was observed. 
This work represents the first mixed- effect model- based analysis of chimeric antigen receptor–T cell therapy and may be 
clinically impactful as future studies examine prophylactic interventions in patients at risk of higher grade cytokine release 
syndrome and the effects of these interventions on chimeric antigen receptor–T cell expansion.
Chimeric antigen receptor (CAR)–T cell therapy involves the 
adoptive transfer of autologous T cells genetically modified 
to facilitate antigen- specific cell killing through endogenous 
effector cell mechanisms of cytotoxicity.1 Unlike canonical 
drug therapies that can be described by classical phar-
macokinetics (PK), CAR- T cells undergo rapid expansion 
several logs beyond the infused cell dose and demonstrate 
long- term persistence that does not follow typical models 
of metabolism and clearance. Characterization of the cellu-
lar kinetics of CAR- T cells as well as factors impacting ki-
netics are important for understanding the efficacy, safety, 
and recommended dose ranges.
Tisagenlecleucel (CTL019) is a CAR- T cell immuno-
therapy that produces durable responses in pediatric and 
young adult patients with relapsed or refractory B cell 
acute lymphoblastic leukemia (r/r B- ALL).2,3 This treatment 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
✔  Tisagenlecleucel is a chimeric antigen receptor (CAR)–T 
cell therapy that facilitates the targeted cell killing of CD19+ B 
cells and provides robust responses in acute lymphoblastic 
leukemia and diffuse large B cell lymphoma. However, com-
prehensive cellular models that describe CAR- T cell kinetics 
are lacking. 
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  A model- based analysis was used to characterize the 
kinetics of tisagenlecleucel therapy and to assess the 
 impact on expansion of intrinsic and extrinsic factors, with 
a focus on comedications for treating cytokine release 
 syndrome (tocilizumab and corticosteroids).
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  This work represents the first mixed- effect model- based 
analysis of CAR- T cell therapy. No impact of tocilizumab or 
corticosteodis on the expansion rate was observed.
HOW MIGHT THIS CHANGE DRUG DISCOVERY, 
DEVELOPMENT, AND/OR THERAPEUTICS?
✔  This work provides a methodology for future studies in 
patients at risk of severe adverse events for assessing the 
impact of earlier anti–cytokine release syndrome therapy, 
which may impede CAR- T cell kinetics or efficacy.
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paradigm genetically modifies autologous T cells to ex-
press a bioengineered CAR that will facilitate the targeted 
killing of CD19+ B cells.  Following infusion, widespread 
distribution of tisagenlecleucel into various tissues oc-
curs within a few hours.4 During the next several days, 
increases in the tisagenlecleucel copy number reflect 
exponential growth, whereby tisagenlecleucel binding to 
its target antigen induces the killing of the target cell and 
stimulates proliferation of the CAR- T cells. After the time 
of maximal expansion (Tmax) is reached, the kinetics of ti-
sagenlecleucel expansion are followed by a biexponential 
decline. The initial contraction occurs at a rapid rate and is 
thought to correspond to programmed cell death of acti-
vated CAR- T cells.5 The second phase of tisagenlecleucel 
decline occurs more gradually over time and corresponds 
to the persistence of CAR- T cells that demonstrate an im-
mune memory phenotype.6
The initial distribution of tisagenlecleucel after the admin-
istered cell dose depends largely on the complex interplay 
between T-cell trafficking, migration from peripheral blood 
to the bone marrow and other secondary lymphoid tissues, 
and the immune activation of tisagenlecleucel through bind-
ing of CD19 antigen on the surface of B cells. This unique 
pharmacology, including an initial characterization of the 
kinetics of tisagenlecleucel expansion, has previously been 
reported in single- center studies that included pediatric 
and adult patients with r/r B- ALL and patients with chronic 
lymphocytic leukemia.7 The results from these prior studies 
demonstrated (i) higher expansion of tisagenlecleucel in pe-
ripheral blood in responding patients than in nonrespond-
ing patients, (ii) higher grades of cytokine release syndrome 
(CRS) in patients with higher baseline tumor burden and 
greater expansion,7 and (iii) the significance of long- term tis-
agenlecleucel expansion and persistence in producing dura-
ble responses in patients with chronic lymphocytic leukemia 
and those with acute lymphoblastic leukemia.
Cytokine release syndrome typically occurs within 
1–22 days of tisagenlecleucel infusion and is an on- target 
toxicity that results from tisagenlecleucel activation, expan-
sion, and tumor- cell killing.3 Because CRS is an on- target 
effect, CRS and efficacy are correlated. CRS is associated 
with increased serum levels of proinflammatory cytokines, 
including interleukin (IL)- 6.1 Although CRS has been suc-
cessfully managed in some pediatric and young adult pa-
tients with r/r B- ALL using supportive care, patients with 
severe CRS have shown benefit from tocilizumab (anti–IL- 6 
receptor antibody) treatment and in some instances treat-
ment with corticosteroids to further control CRS symp-
toms. Tocilizumab has been approved by the US Food and 
Drug Administration for treating CRS and among patients 
receiving tisagenlecleucel or axicabtagene ciloleucel, and 
it was observed that 69% of patients were responders.8 
There is a potential for these comedications to impact the 
CAR- T cells because corticosteroids are known to reduce 
circulating T cells9 and induce apoptosis,10 and tocili-
zumab is an anti- inflammatory medication that could also 
potentially impact T cells. Mueller and colleagues7 previ-
ously reported that tisagenlecleucel continues to expand 
and persist following the administration of tocilizumab and/
or steroids in patients experiencing severe CRS; however, 
model- based methods characterizing the impact of tocili-
zumab on tisagenlecleucel expansion have not been pre-
viously described. A model- based approach allowed us to 
assess whether anti- inflammatory therapy would alter the 
expansion profile of the patient who receives it.
In this analysis, a nonlinear, mixed- effects modeling ap-
proach was used to characterize the impact of tocilizumab 
therapy on the kinetics of in vivo tisagenlecleucel expansion. 
The primary focus of this work was to investigate the differ-
ences in peak tisagenlecleucel levels and the rates of tisagen-
lecleucel expansion in patients who underwent tocilizumab 
or corticosteroid therapy when compared with patients who 
did not require these treatments for CRS to assess whether 
anti- inflammatory therapy would alter the tisagenlecleucel 
expansion profile in the patients who receive it.
METHODS
Data
Data from two phase II studies of pediatric and young 
adult B- ALL (NCT02435849 (ELIANA) and NCT02228096 
(ENSIGN)) were used for this analysis.  ELIANA is an ongo-
ing global trial that included 62 patients from 10 countries 
at the time of data cutoff, August 17, 2016. ENSIGN is a US 
multicenter trial that enrolled a total of 29 patients at the 
time of data cutoff, February 1, 2016. Both clinical studies 
have near- identical enrollment and treatment protocols, al-
lowing data to be pooled for analyses. The patients received 
a single dose of tisagenlecleucel. The median weight- 
adjusted dose was 3.1 × 106 CAR- positive viable T cells 
per kg (range, 0.2–5.4 × 106 cells/kg) for patients weighing 
≤50 kg, and the median total dose of CAR- positive viable T 
cells was 1.0 × 108 (range, 0.03–2.6 × 108 cells) for patients 
weighing > 50 kg. The patient outcomes from interim analy-
ses have been previously reported.2,11
Both studies were approved by the institutional review 
boards at each participating institution and conducted in 
accordance with the Declaration of Helsinki. ELIANA was 
sponsored and designed by Novartis Pharmaceuticals 
Corporation and ENSIGN was designed by the University 
of Pennsylvania and sponsored in conjunction with Novartis 
Pharmaceuticals Corporation. The patients or their guard-
ians provided written informed consent or assent.
Sample analysis
Tisagenlecleucel levels, reported as transgene copies/μg 
of genomic DNA, were measured in 90 patients (ELIANA, 
N = 61; ENSIGN, N = 29) using quantitative polymerase 
chain reaction (qPCR). Briefly, genomic DNA was isolated 
from samples of peripheral blood, and transgene cop-
ies were quantified using TaqMan technology (Applied 
Biosystems, Foster City, CA) and transgene- specific prim-
ers. A validated assay was used to detect integrated trans-
gene sequences.7,12 To ensure quality control, a parallel 
amplification reaction was performed using a primer- probe 
combination specific to a nontranscribed sequence up-
stream of the cyclin- dependent kinase inhibitor 1A gene, 
p21, CDKN1A.6 Amplification of the reference sequence was 
used to normalize the absolute quantification of the CD19 
CAR transgene. The limit of quantification was 10 copies per 
reaction (≈ 50 transgene copies per μg of genomic DNA). 
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The samples were collected at days 1, 2, 7, 11, 14, 21, and 
28 and followed by 3- month intervals from months 3–12 and 
then 6- month intervals until month 60. Day 1 corresponded 
to the day of infusion or first dose of tisagenlecleucel. In this 
study, tisagenlecleucel levels were also measured by flow 
cytometry. Good correlation between flow cytometry and 
qPCR was observed, and qPCR was selected for this anal-
ysis because it was a more sensitive assay,7 allowing for 
better characterization of long- term persistence.
Model- based analysis of tisagenlecleucel
Base model. The base structural model is adapted from a 
previously published empirical model used to describe the 
murine immune responses to Listeria monocytogenes or 
lymphocytic choriomeningitis virus, in which similar profiles 
of lymphocyte kinetics were observed; we use the analytical 
solution to equation 7 from DeBoer and Perelson.4 The 
structural model captures the exponential expansion of 
tisagenlecleucel with rate constant ρ up to time Tmax, followed 
by biexponential contraction after Tmax with rate constants 
α and β. The α slope corresponds to a rapid contraction as 
a result of the programmed apoptosis of most activated 
lymphocytes following the initial immune response, and 
the β slope corresponds to a gradual decrease of T cells 
that can persist in the body for years or even decades.13–15 
A typical model profile is shown in Figure 1a. The model 
has the following six fixed parameters: Cmax, Tmax, foldx, 
FB, α, and β. Cmax is the maximum transgene copies of 
tisagenlecleucel that occurs at time Tmax; foldx is the fold 
expansion of tisagenlecleucel from baseline and is given by 
foldx = exp(ρ·Tmax), where ρ =  log(foldx)/Tmax. FB describes 
the fraction of transgene copies present at peak expansion 
(Tmax), which decline with gradual rate constant β, and 
(1 − FB) is the fraction of transgene copies present at peak 
expansion, which decline with the rapid rate constant α.
For the base model, the terms R0, A, and B in the equations 
were computed as follows to ensure continuity: R0 = Cmax/
foldx, R0 is the baseline transcript levels in Eq. 1; A = Cmax 
(1 − FB); B  =  Cmax·FB. A and B correspond to a portion of Cmax 
that declines rapidly (at slope α) and more gradually (at slope 
β) at time Tmax. These parameters were employed in Eq. 1.
The above model equations are empirical in nature and 
describe the available data. The equations above are also 
described by the semimechanistic compartmental model in 
Figure 2.4 Effector CAR- T cells can expand exponentially 
(ρ) up until time Tmax and then decline (α − k) or transition to 
memory cells (k) such that the total rate constant for the de-
cline of this population at time Tmax is α, which then persist 
and decline with a rate constant β.6 The analytical solution 
to this compartmental model gives rise to Eq. 1 describ-
ing the PK of tisagenlecleucel (Supplementary Material). 
Other semimechanistic models can also give rise to similar 
kinetics, as described in the Discussion section.
Comedication effect on expansion. As mentioned 
previously, CRS is an on- target toxicity associated with 
tisagenlecleucel activation and cellular expansion and in 
some cases requires the use of tocilizumab or corticosteroids 
to ameliorate severe symptoms and mitigate inflammatory 
organ damage. The key objective of this analysis was to 
study the impact of tocilizumab and corticosteroids on 
tisagenlecleucel expansion as used per the treatment 
algorithm16 outlined in the study protocol. The following two 
relationships between expansion and the comedications for 
treating CRS were explored: (i) treatment with tocilizumab 
and/or corticosteroids may slow the rate of expansion 
of tisagenlecleucel, and (ii) the requirement of treatment 
for CRS may be predictive of Cmax because patients with 
(1)f (t)=
{
R0e
ρt , t<Tmax
Ae−α(t−Tmax)+Be−𝛽(t−Tmax), t≥Tmax
Figure 1 Graphical representation of the cellular kinetic models. 
(a) The graph depicts the mathematical model of tisagenlecleucel 
following expansion at a rate (ρ) up to time to maximal expansion 
(Tmax), followed by a biphasic contraction at rates α and β. 
Because FB is much <1, the initial decline rate is well estimated 
by α. (b) Mathematical model for tisagenlecleucel expansion 
concurrent with tocilizumab and corticosteroid administration 
given at times Ttoci and Tster, respectively. The model allows for a 
reduced rate of expansion with Fster, effect of steroids, and Ftoci, 
effect of tocilizumab. FB, fraction of transgene copies present 
during the decline at the gradual rate β, starting from Tmax; 
Fster, effect of steroids; Ftoci, effect of tocilizumab; Tster, time to 
maximal expansion with steroid therapy; Ttoci, time to maximal 
expansion with tocilizumab therapy.
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higher exposure are more likely to have CRS and receive 
tocilizumab.7,17
The impact of tocilizumab or corticosteroids on the expan-
sion rate was explored by expanding the structural model to 
include a tocilizumab and corticosteroid effect on ρ in Eq. 2 
(see also Figure 1b). Here, T1 is the time of administration 
for the first comedication, and T2 was the time of administra-
tion for the second comedication. F1 and F2 correspond to 
the effect of each comedication on the growth rate ρ, where 
F < 1 indicates a decrease in expansion rate as a result of 
the comedication. The CRS treatment algorithm specifies 
that tocilizumab be given first, followed by corticosteroids; 
thus, for most patients, F1 = Ftoci (effect of tocilizumab) and 
F2 = Fster (effect of steroids).
16 However, if the patient re-
ceived corticosteroids for other clinical conditions unrelated 
to CRS, a corticosteroid dose could occur first. Although 
some patients received multiple doses of tocilizumab and 
corticosteroids, only the impact of the first dose was mod-
eled. Because the corticosteroid administered was almost 
always after tocilizumab administration (with the exception 
of one patient who had an allergic reaction), an interaction 
term was not included in the model.
The new constants R1 and R2 are given by R1 = R0 ⋅e
ρT1 
and R2 = R1 ⋅e
ρ⋅F1(T2−T1).
The relationship between comedications and Cmax was 
explored by including binary covariate effects on Cmax, de-
scribed further below. Although either comedication could po-
tentially impact any of the other model parameters, no other 
effects were explored, as explained in the Discussion section. 
Other comedications for CRS (e.g., IL- 6 and TNFα antago-
nists) were not modeled because only 10 patients received 
such drugs.  The Monolix code for this model is given in the 
Supplementary Material
Random- effect model. Six random effects were included 
on the following parameters: Cmax, foldx, Tmax, FB, α, and β 
(Table 1); all parameters were assumed to be log- normally 
distributed. For the residual error model, log- transformed data 
were modeled with a proportional error model (constant error 
model in log- space), which is typical for the qPCR assay.18
Covariate model. Cmax was chosen as the main covariate 
because it could be directly linked to area under the curve 
(AUC) by integrating Eq. 1, which gives the equation below 
(Supplementary Material):
This relationship indicates that intrinsic and extrinsic 
factors that impact Cmax will also impact AUC. The factors 
(2)f (t)=
⎧⎪⎨⎪⎩
R0e
ρt , t<T1
R1e
F1⋅ρ(t−T1), T1≤ t<T2
R2e
F1F2⋅ρ(t−T2), T2≤ t<Tmax
Ae−α(t−Tmax)+Be−β(t−Tmax), t≥Tmax
AUC0−∞ =Cmax[1∕ρ+ (1−FB)∕α+FB∕β]
Figure 2 Compartmental model describing T-cell kinetics. The model has exponential growth of effector cells (E) at rate ρ before time to 
maximal expansion (Tmax). After Tmax, effector cells rapidly decline at rate (α- k) and convert to memory cells at rate k; the memory cells then 
decline at a rate β. The rapid decline is most likely caused by programmed cell death following immune activation, and a slower decline rate 
is indicative of a longer persistence of the memory effector T-cell phenotype. The equations describing the rates of expansion and decline 
are shown. Additional information about the model can also be found in the Supplementary Material. Cmax, maximal concentration; FB, 
fraction of transgene copies present during the decline at the gradual rate β, starting from Tmax; foldx, fold expansion; Fster, effect of steroids; 
Ftoci, effect of tocilizumab; Tster, time to maximal expansion with steroid therapy; Ttoci, time to maximal expansion with tocilizumab therapy.
Compartmental model
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affecting persistence were also of interest but were not ex-
plored for reasons explained in the Discussion section.
The categorical covariates explored in this model in-
cluded sex, race, Down syndrome, prior lymphodepleting 
chemotherapy with fludarabine (when added to cyclophos-
phamide), and prior stem cell transplant. Continuous covari-
ates included age (< 10, 10–17, ≥18 years), weight- adjusted 
dose, time to first tocilizumab dose, time to first corticoste-
roid dose, transduction efficiency of manufactured product, 
and patient weight. In some cases, there were very few pa-
tients in a particular category; therefore, this analysis should 
be treated as only exploratory. It is possible that differences 
in Cmax may be related to other factors, such as differences 
in CD19 antigen density or variation in the capacity of a pa-
tient’s autologous T cells to proliferate, although such data 
were not collected in these trials.
The covariates were explored by bootstrapping the full co-
variate model, where the data set was resampled and the full 
model refit 500 times.19 In this analysis, the covariate analy-
sis is done only for exploratory purposes and not to impact 
dose selection. Therefore, the full model is selected as the 
final model in this analysis. Further details on the motivation 
for choosing the covariates and how the covariate analysis 
was performed are provided in the Supplementary Material.
Analysis. The Monolix software system (Lixoft, Antony, 
France) was used to estimate population parameters using 
the CENSSORING column to denote data below the limit 
of quantitation. Below the limit of quantitation assessments 
were treated as fixed- point censored data. A simulated 
data set is provided in Data set S1 and the mlxtran code 
used for fitting the model is provided in the Supplementary 
Material. The technical computing packages R and Matlab 
were used for some exploratory analysis, model building, 
and reporting the final results.
RESULTS
Analytical model of tisagenlecleucel cellular kinetics
The base model was applied to a patient cohort (n = 90) 
that included pediatric and young adult patients with r/r 
B- ALL who were treated with a single dose of tisagenlec-
leucel. There were 836 measurements with 43 below the 
limit of quantification. Patient characteristics are shown 
in Table 2. The base model characterized the data well, 
Table 1 Model parameters
Type Parameter Units Estimate RSE, % Eta shrinkage
Fixed effect foldx — 3,900 30 —
Fixed effect Tmax Days 9.3 4.2 —
Fixed effect Cmax DNA copies/μg 24,000 20 —
Fixed effect Ftoci — 1.2 7.5 —
Fixed effect Fster — 1 9 —
Fixed effect α 1/day 0.16 11 —
Fixed effect FB — 0.0079 15 —
Fixed effect β 1/day 0.0032 23 —
Random effect foldx — 2.4 9.5 0.39
Random effect Tmax — 0.38 7.9 0.14
Random effect Cmax — 0.65 10 0.29
Random effect α — 0.91 8.8 0.27
Random effect FB — 0.8 15 0.53
Random effect β — 0.86 23 0.82
Residual error a — 0.56 3.3 —
Log Cmax covariate effect Female (vs. male) — 0.25 72 —
Log Cmax covariate effect Asian (vs. white) — 0.13 250 —
Log Cmax covariate effect Race other/unknown 
(vs. white)
— 0.33 76 —
Log Cmax covariate effect Down syndrome — 0.25 130 —
Log Cmax covariate effect Received HSCT — 0.29 62 —
Log Cmax covariate effect No fludarabine received — −0.63 69 —
Log Cmax covariate effect Study B2205J vs. 
B2202
— −0.11 190 —
Log Cmax covariate effect Transduction efficiency — 0.22 72 —
Log Cmax covariate effect Dose normalized by 
body weight
— 0.093 140 —
Log Cmax covariate effect Received tocilizumab — 0.44 59 —
Log Cmax covariate effect Received 
corticosteroids
— −0.36 75 —
Cmax, maximal concentration; Eta shrinkage, shrinkage of empirical Bayes estimates of the parameter; FB, fraction of transgene copies present during the 
decline at the gradual rate β, starting from Tmax; foldx, fold expansion of tisagenlecleucel from baseline; Fster, effect of steroids; Ftoci, effect of tocilizumab; 
HSCT, hematopoietic stem cell transplant; RSE, relative standard error of the parameter; Tmax, time to maximal expansion.
foldx is computed by the equation foldx = exp(ρ·Tmax). Eta shrinkage for each parameter is calculated by the formula (1 − var(η))/ω
2.
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as shown by the visual predictive check and individual 
fits in Figure 3, with additional diagnostics included in 
the Supplementary Material. The model parameters are 
summarized in Table 1. The initial doubling time (ln 2/ρ) 
was 0.78 days, the half- life for the initial rate of decline 
(ln 2/α) was 4.3 days, and the terminal half- life (ln 2/β) was 
220 days.  Because the longest follow- up for this analysis 
was only 1 year (Figure 3a), this terminal half- life estimate 
must be interpreted with caution and will be updated as 
more data become available.
Because rich sampling was collected in all patients, the 
Cmax and AUC from days 0–28 could be directly computed 
for most patients in this study by noncompartmental analy-
sis (NCA). Good correlation between the NCA estimates 
and the model- computed NCA parameters was observed 
(Supplementary Material).
Impact of tocilizumab/corticosteroids on 
tisagenlecleucel expansion
The impact of tocilizumab and corticosteroids on the expan-
sion rate constant is summarized in Table 1, which shows that 
Ftoci and Fster were both close to 1. Thus, neither was found 
to impact the rate of expansion. This can also be observed 
in Figure 4, which shows the individual fits for all patients 
who had rich qPCR data (≥ 6 data points in first 2 weeks) and 
who received their first tocilizumab dose on or before day 
6. The rates of expansion (slope of qPCR curve) before and 
after tocilizumab or corticosteroids appear similar, suggest-
ing that treatment with tocilizumab or corticosteroids may 
not impact the rate of tisagenlecleucel expansion. It should 
be noted that in some patients (e.g., patient BB in Figure 4), 
the first dose of tocilizumab was given only a few days be-
fore Cmax had been achieved; therefore, in some cases, the 
true impact of tocilizumab on expansion may be difficult to 
assess. Although most patients receive tocilizumab prior to 
corticosteroids, as specified by the CRS treatment protocol, 
one patient (patient EE in Figure 4) received corticosteroids 
first as the result of an allergic reaction.16
Covariate analysis
Exploratory plots were used to screen all covariates 
(Supplementary Material), and the results from boot-
strapping the full covariate model showed no statistically 
significant impact of any covariate on the maximal concen-
tration of tisagenlecleucel (Table 1). Because no covariates 
had a statistically significant impact on the cellular kinetic 
parameters of tisagenlecleucel expansion, we concluded 
that the final cellular kinetic model was the same as the 
base model. Mueller and colleagues7 demonstrated that 
a larger preinfusion tumor burden was associated with in-
creased tisagenlecleucel expansion; however, preinfusion 
tumor burden after lymphodepletion was not measured in 
these studies.
Although the administration of tocilizumab or corticoste-
roids did not appear to impact the rate of expansion, we 
explored the possibility of a correlation between comed-
ication treatment and Cmax because patients with greater 
peak transgene levels were more likely to have grade 3 or 4 
CRS and were therefore more likely to receive comedication 
treatment. The model- estimated Cmax was twofold higher in 
patients who required tocilizumab and was similar to that in 
the previously published NCA.7
DISCUSSION
Classical pharmacological agents, such as small mole-
cules or monoclonal antibodies, can be described using 
standard compartmental approaches to estimate the PK 
parameters. The distribution, metabolism, and excretion 
of small molecules and monoclonal antibodies are largely 
driven by the biophysical properties of the molecule and 
the plasma concentrations that result after absorption. 
However, the kinetics of cell- based therapies are more 
complex and are influenced by the physiological func-
tions of the targeted cell type and by cell- extrinsic fac-
tors, such as the abundance of the CAR target molecule 
in vivo. The major differences between the CAR- T cellular 
kinetic model and a traditional PK model are summarized 
in Table 3 and listed below.20,21
Applicability of standard PK parameters
Unlike a traditional drug, CAR- T cells have the capacity to 
proliferate. For this reason, traditional PK parameters such 
as clearance and volume of distribution are not applicable 
and were not computed as part of the NCA.7
Mechanism of biphasic decline
For a typical drug, the α and β slopes arise from the inter-
play of two processes, distribution of the drug from the 
blood to peripheral tissues and elimination of the drug from 
the body. However, elimination of T cells from the body is 
Table 2 Patient characteristics
Characteristic Patients (N = 90)
Sex, male/female, % 50/50
Age, median (range), years 12 (3–25)
Weight, median (range), kg 39 (14–140)
Race, %
White 77
Asian 9
Other/unknown 14
Down syndrome, % 8
Previous stem cell transplant, % 57
Lymphodepleting chemotherapy with 
fludarabine, %
94
Weight- adjusted dose of tisagenle-
cleucel, median (range), cells/kg
3.1 × 106 (0.2–5.4 × 106)
Total dose of tisagenlecleucel, 
median (range), cells
1.0 × 108 (0.03–2.6 × 108)
Transduction efficiency, median 
(range), %
19 (2.3–56)
Tisagenlecleucel cell viability, median 
(range), %
94 (55–99)
Received steroids, % 26
Timing of first steroid dose, median 
(range), days
7.5 (0.11–170)
Received tocilizumab, % 36
Timing of first tocilizumab dose, 
median (range), days
5.7 (1–27)
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Figure 3 Model fits. (a) Visual predictive check of the model simulation compared with the data. The blue dots show the transgene 
copies per μg of genomic DNA, and the red asterisks denote simulated data points for the measurements that were below the limit of 
quantification (BLQ) of 50 transgene copies per μg. The blue lines show the 10th, 50th, and 90th percentiles calculated directly from 
the population data; the blue- shaded areas denote the confidence intervals of the 10th and 90th percentiles from the model; and the 
pink shaded area shows the 50th percentile. The empirical percentiles lie within the confidence intervals, except at day 5, indicating 
that overall the model describes the data well. (b) Individual fits for tisagenlecleucel transgene copies per μg of genomic DNA (y- axis) 
over time in months from CAR- T cell infusion (x- axis) observed in a representative set of patients. CAR, chimeric antigen receptor 
qPCR, quantitative polymerase chain reaction.
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Figure 4 Individual fits for a subset of all patients with rich quantitative polymerase chain reaction (qPCR) sampling who received 
tocilizumab and/or corticosteroids. The red dashed lines indicate treatment with corticosteroids, and the green lines indicate treatment 
with tocilizumab. Each dot represents a measurable qPCR value. Black horizontal lines indicate the limit of quantification equal to 50 
transgene copies per μg of genomic DNA. BLQ, below the limit of quantification.
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Table 3 Difference between kinetics of a small-molecule oral dose and CAR- T cell therapy
Property Small molecule CAR- T cell17,24
Ability to proliferate No Yes
Reason for α and β phase Distribution and elimination Contraction and persistence
Terminal half- life time scale Hours, days, or weeks Years
Applicability of traditional NCA parameters 
(clearance and volume of distribution)
Applicable Not applicable because of the ability of CAR- T cells 
to proliferate
Variability in product from patient to patient None Variability exists because of variability in patient 
immune systems
Clear relationship between dose and 
exposure
Yes, although it may be nonlinear No relationship between dose and exposure 
detected
Kinetic equation following small-molecule 
oral dose or intravenous CAR- T cell dose
A·exp(−αt) + B·exp(−βt) − (A + B)·exp(−kat)
f (t)=
{
R0e
ρt , t<Tmax
Ae−α(t−Tmax)+Be−β(t−Tmax), t≥Tmax
Sign of exponent for initial increase after 
dosing
Negative (−ka) Positive (+ρ)
CAR, chimeric antigen receptor; NCA, noncompartmental analysis; Tmax, time to maximal expansion.
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governed by fundamentally different mechanisms. The α 
slope corresponds to a rapid contraction because of the 
programmed apoptosis of most activated lymphocytes 
following the initial immune response, and the β slope cor-
responds to a gradual decline of memory cells, which can 
persist in the body for years or even decades.13,14 Although 
the persistence phase of tisagenlecleucel has kinetics simi-
lar to that of long- term memory cells, it may also be that the 
persistence is the result of the continual production of B cell 
precursors expressing CD19, with the surrogate antigen act-
ing as an endogenous vaccine. In this respect, the long per-
sistence of CD19 CAR- T cells may be similar to T cells that 
are specific for latent viruses such as cytomegalovirus.22
The model presented in Figure 2 is not the only semi-
mechanistic model that gives rise to exponential growth 
followed by biexponential decay in Eq. 1. If memory cells 
were produced during the expansion phase as well or if cells 
could transition back and forth from the effector to mem-
ory states, then the analytic solution to such a model would 
have the same functional form. It is also possible that the 
terminal phase is not a result of the formation of memory 
cells but rather the low level of constant proliferation in re-
sponse to the continual production of the CD19 antigen; the 
kinetics of this process would also look similar. DeBoer and 
Perelson4 also showed in equations 8–10 of their paper that 
rather than have expansion stop at Tmax, one could use a 
“cascade” model of cell division, modeling each generation 
of expansion. Although this model is more realistic, it be-
haves similarly to the simpler model used here.
Distribution
Similar to a traditional drug, tisagenlecleucel has the ca-
pacity to distribute to other tissues within the body. 
Lymphocytes can traffic to the bone marrow, gut, spleen, 
and lymph nodes, with peripheral blood containing only 2% 
of the total body lymphocyte population.19 The bone marrow 
CAR- T cell population, where progenitor B cells expressing 
CD19 are continually produced, may be more important 
than blood for establishing relationships between the cellu-
lar kinetics of tisagenlecleucel and safety and efficacy.
Long- term persistence
In the current analysis, the longest follow- up time was ap-
proximately 1 year, thus limiting the accuracy of the estimate 
for the terminal half- life. For this reason, a covariate analysis 
of the terminal half- life was not performed. However, lon-
ger persistence for CAR- T cells has been observed.7 Two 
of the first three patients treated with tisagenlecleucel in 
2010 currently maintain low but stable levels of CAR- T cells 
and have B cell aplasia now, 8 years later. In patients with 
HIV treated with CD4ζ CAR- T cells, the average half- life of 
the CAR- T cell in peripheral circulation has been reported 
to be 17–23 years.15  As tisagenlecleucel- treated patients 
remain in follow- up in these trials, this analysis will be up-
dated such that a better estimate of the terminal half- life 
can be obtained.
Model equations
Because CAR- T cells have the capacity to proliferate beyond 
the initial dose infused and the mechanism of elimination is 
different than that of traditional drugs, it is necessary to use 
a different structural model to describe the cellular kinet-
ics than the standard compartmental models used for the 
population PK of traditional drugs. Although the profile in 
Figure 1a may look similar to a standard two- compartment 
PK model describing oral absorption of a small molecule, 
the kinetics of tisagenlecleucel is driven by fundamentally 
different processes that require different mathematical 
equations to model expansion and persistence. In partic-
ular, the cellular kinetic model describes the exponential 
expansion of the tisagenlecleucel transgene levels with 
positive exponent ρ. This contrasts with the standard two- 
compartment model with oral absorption, where all expo-
nents are negative, as shown in the analytical solution in 
Table 3.
No relationship between dose and exposure
Unlike a traditional drug, no relationship was detected be-
tween tisagenlecleucel dose and Cmax or any other model 
parameter (Supplementary Figure S2a). Although a dose- 
exposure relationship is generally expected for most drugs, 
the lack of a relationship here may be a result of the capac-
ity of tisagenlecleucel to proliferate in vivo and heterogene-
ity across a patient’s product, native immune system, and 
tumor burden.
Differences between CAR- T kinetics and traditional 
immune kinetics
Unlike in natural immune responses, where thymic output 
contributes new cells into the peripheral compartment,5 
there is no de novo generation of CAR- T cells. However, 
there is de novo generation of the CD19+ antigen, so it is not 
clear if the persistent cells are true memory cells or if they 
continually proliferate at a low rate in response to antigen.
Effect of tocilizumab and corticosteroids on 
expansion
A twofold higher Cmax was observed in patients that re-
ceived tocilizumab. This is thought to be because patients 
with greater expansion are more likely to develop grades 
3 and 4 CRS and are therefore more likely to require to-
cilizumab therapy. An impact of tocilizumab therapy on the 
rate of expansion was not detected. As shown in Figure 4, 
individual fits of patient data showed no changes in the rate 
of expansion of tisagenlecleucel before and after the ad-
ministration of tocilizumab, and some patients had a ≥ 10- 
fold increase in tisagenlecleucel levels even after receiving 
their first dose of tocilizumab for CRS. Given this obser-
vation, no further analysis was performed on patients who 
received a second dose of tocilizumab. These data suggest 
that greater tisagenlecleucel expansion (Cmax) leads to an 
increased likelihood of CRS, and therefore, a correlation ex-
ists between tocilizumab administration and exposure.7,17 
However, it is important to note that these analyses did not 
examine the impact of the prophylactic use of tocilizumab 
to treat CRS on Cmax; assessing prophylactic tocilizumab 
would need to be done in a carefully controlled clinical trial.
Although the analyses presented herein demonstrate 
that corticosteroids and tocilizumab did not impact the 
Cmax, it is important to recognize that corticosteroids were 
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administered at low doses during a short duration and that 
the patients were weaned rapidly. The CRS treatment algo-
rithm used in ELIANA and ENSIGN specified that corticoste-
roids be given only when the first dose of tocilizumab did not 
lead to an improvement in CRS. Furthermore, methylpred-
nisolone doses were ≤ 2 mg/kg per day. Thus, the effects 
of giving corticosteroids at higher doses before tocilizumab, 
without tocilizumab, or before the development of severe 
CRS were not assessed.
None of the other covariates explored (including cortico-
steroid dosing) were confirmed to have an effect on Cmax. 
Although it has been observed elsewhere that baseline 
tumor burden also correlates with an increased expansion,23 
this was not assessed because in the ELIANA and ENSIGN 
trials, bone marrow biopsies were not collected after lym-
phodepletion but before tisagenlecleucel dosing.
This work represents the first mixed- effect model- based 
analysis of a CAR- T cell therapy and may have broad ap-
plication to multiple CAR treatment platforms. Our cellular 
kinetic model may be adapted to characterize the expansion 
and persistence of genetically modified cells across multiple 
disease indications, within various cell types, and between 
different costimulatory domains. A fundamentally different 
model structure was needed to describe these data than 
is used for standard population cellular kinetic models be-
cause CAR- T cells can proliferate exponentially and expand 
> 1,000- fold in most patients. The model consistently de-
scribed aggregate data and individual patient data, and the 
cellular kinetic analysis provided similar results to those in the 
previous NCA.7 Patients with higher peak transgene levels 
were more likely to receive tocilizumab, consistent with prior 
results, on the basis of NCA.24 Finally, no effect of tocilizumab 
and corticosteroids on the rate of expansion was observed.
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